[
  {
    "ts": null,
    "headline": "Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025",
    "summary": "TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s web",
    "url": "https://finnhub.io/api/news?id=164ee86d40c9ce5a3454b286394190efc726e6cba0ab4e930399e78aa355713f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759262700,
      "headline": "Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025",
      "id": 136944453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s web",
      "url": "https://finnhub.io/api/news?id=164ee86d40c9ce5a3454b286394190efc726e6cba0ab4e930399e78aa355713f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Growth Catalysts Incoming",
    "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249535,
      "headline": "Regeneron: Growth Catalysts Incoming",
      "id": 136939389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34"
    }
  },
  {
    "ts": null,
    "headline": "2 Beaten-Down Stocks to Buy and Hold for a Decade",
    "summary": "These biotechs should benefit from their innovative ways.",
    "url": "https://finnhub.io/api/news?id=ebfeedc9457194311eb3283ab90cc23d011a31fffb3df2d25bfbb93aff2e410a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759231800,
      "headline": "2 Beaten-Down Stocks to Buy and Hold for a Decade",
      "id": 136936257,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "These biotechs should benefit from their innovative ways.",
      "url": "https://finnhub.io/api/news?id=ebfeedc9457194311eb3283ab90cc23d011a31fffb3df2d25bfbb93aff2e410a"
    }
  },
  {
    "ts": null,
    "headline": "4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors",
    "summary": "4D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene therapy programs. See more here.",
    "url": "https://finnhub.io/api/news?id=11047894b76e872e1eb68c2fdf7e1637620641174a99a06f99052495f779a2e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759208894,
      "headline": "4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors",
      "id": 136933764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227849831/image_2227849831.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "4D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene therapy programs. See more here.",
      "url": "https://finnhub.io/api/news?id=11047894b76e872e1eb68c2fdf7e1637620641174a99a06f99052495f779a2e2"
    }
  }
]